Monika Pazgan‐simon - Infectious Diseases

Author Information

Monika Pazgan-Simon is affiliated with the Department of Infectious Diseases at Wroclaw Medical University and the 1st Department of Infectious Diseases at J. Gromkowski Specialist Regional Hospital, both located in Wrocław, Poland. Her research primarily focuses on infectious diseases, with significant contributions to understanding COVID-19 and liver-related conditions.

Research Contributions

Monika Pazgan-Simon has made notable contributions to the field of infectious diseases, particularly concerning COVID-19 and liver disease. Her work on liver injury in COVID-19 patients without underlying liver conditions and breakthrough COVID-19 cases during the Delta variant's prominence in Poland has been pivotal. Moreover, she has extensively researched hepatocellular carcinoma, as evidenced by her studies on Tumor Treating Fields in conjunction with sorafenib. Her investigations into the clinical characteristics and outcomes of hospitalized COVID-19 patients, alongside her work on the effectiveness of direct-acting antivirals in hepatitis C patients, underscore her significant role in advancing infectious disease research.

Aliases

Monika Pazgan-Simon is also known by several aliases, including M Pazgan-simon, M. Pazgan-simon, and Monika Pazgan–Simon.

Publication and Citation Metrics

Metric	Value
Total Citation Count	600
H-index	13
Total Number of Papers	69

Publications:

Liver Injury in Patients with COVID-19 without Underlying Liver Disease

DOI: 10.3390/jcm11020308

Year: 2022

Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study

DOI: 10.3390/cancers14061568

Year: 2022

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland

DOI: 10.3390/vaccines10040557

Year: 2022

Simple Demographics and Laboratory Findings on Admission May Predict f In-hospital Mortality in Patients with SARS-CoV-2 Infection

DOI: 10.21203/RS.3.RS-558426/V1

Year: 2021

SARS-CoV-2 infection: etiopathogenesis, clinical picture, current therapeutic options – the author’s observations

DOI: 10.5603/NJO.2021.0006

Year: 2021

Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy

DOI: 10.3390/cancers13153694

Year: 2021

Simple demographic characteristics and laboratory findings on admission may predict in-hospital mortality in patients with SARS-CoV-2 infection: development and validation of the covid-19 score

DOI: 10.1186/s12879-021-06645-z

Year: 2021

O-16 HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma

DOI: 10.1016/J.ANNONC.2021.05.808

Year: 2021

Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine

DOI: 10.3390/vaccines9070781

Year: 2021

Real‐world effectiveness and safety of direct‐acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi‐Ter2 Study

DOI: 10.1111/liv.14858

Year: 2021

What is a Monogamous Relationship?

How Can Epigenetics Be Used to Combat Infectious Diseases?

What are the Global Health Implications?

What are the Key Factors in Resource Allocation?

Which Infectious Diseases Commonly Cause Fatigue?

What is the Global Impact of Hepatitis B?

How Do Vectors Transmit Diseases?

How is Botulism Transmitted?

Can Condoms Be Used with Other Preventive Measures?

How Can Individuals and Communities Help in WHO’s Efforts?

Partnered Content Networks

Relevant Topics